SPRAVATO is a prescription nasal spray containing esketamine, a derivative of ketamine, and it represents one of the more significant shifts in depression treatment over the past decade. Approved by the FDA in March 2019 for treatment-resistant depression in adults, the drug is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. As of January 2025, it became the first and only standalone monotherapy approved for treatment-resistant depression, meaning patients no longer need to take an oral antidepressant alongside it for that specific indication.
The cost, however, is substantial: a single treatment session runs between $600 and $1,300 depending on the dose, and a full induction course without insurance can reach $16,800 to $27,300. For families navigating brain health challenges, particularly those dealing with depression that coexists with cognitive decline or dementia caregiving stress, SPRAVATO raises important questions. Who actually qualifies? What does the out-of-pocket expense look like with insurance? And what are the real risks, especially for older adults or people already managing multiple medications? This article breaks down the eligibility criteria, pricing realities, side effect profile, and practical considerations for anyone weighing this option.
Table of Contents
- Who Is Eligible for SPRAVATO and What Does Treatment-Resistant Depression Mean?
- How Much Does SPRAVATO Cost With and Without Insurance?
- What Happens During a SPRAVATO Treatment Session?
- SPRAVATO Side Effects and What to Expect After Each Dose
- How SPRAVATO Compares to IV Ketamine Clinics
- Considerations for Older Adults and Dementia Caregivers
- What the 2025 Monotherapy Approval Means Going Forward
- Conclusion
- Frequently Asked Questions
Who Is Eligible for SPRAVATO and What Does Treatment-Resistant Depression Mean?
Treatment-resistant depression is not simply feeling like your antidepressant is not working well enough. The clinical definition requires that a patient has tried at least two different oral antidepressants at adequate doses for adequate durations and still not achieved a satisfactory response. That is a meaningful threshold. Someone who tried one SSRI for three weeks and quit due to side effects would not meet the criteria. A person who spent months on both sertraline and venlafaxine at full therapeutic doses without meaningful improvement would. There are currently two approved patient populations. The first is adults with treatment-resistant depression, who can now use SPRAVATO either as a standalone treatment or alongside an oral antidepressant.
The second is adults with major depressive disorder who are experiencing acute suicidal ideation or behavior. For this second group, SPRAVATO must still be used in conjunction with an oral antidepressant. In both cases, the drug is only available through a REMS program, which means it cannot be picked up at a pharmacy and taken at home. Every dose must be administered in a certified healthcare setting with post-dose monitoring. It is worth noting what SPRAVATO is not approved for: it is not indicated for general anxiety, mild to moderate depression, or depression in adolescents. A caregiver experiencing burnout-related depression, for instance, would need to meet the treatment-resistant threshold before this option would be on the table. That distinction matters because the drug carries real risks that would not be justified for milder cases where other options remain viable.
How Much Does SPRAVATO Cost With and Without Insurance?
The sticker price for SPRAVATO is steep. The 56 mg dose, which uses two spray devices, starts around $882 per session. The 84 mg dose, using three spray devices, starts around $1,319 per session. During the induction phase, patients receive treatment twice weekly for four weeks, which means eight sessions before transitioning to the maintenance phase of once weekly or every two weeks. A full 21-session induction course without insurance runs an estimated $16,800 to $27,300. However, most patients do not pay the full retail price.
According to Janssen, the average out-of-pocket cost for insured patients falls under $500 per month. The company also offers a withMe Savings Card that can reduce copays to as low as $10 per treatment, with a maximum savings benefit of $8,150 per year. Medicare and Medicaid patients typically cannot use manufacturer copay cards, though, which creates a significant gap for older adults on fixed incomes. If you are a dementia caregiver in your sixties dealing with treatment-resistant depression and relying on Medicare, the financial picture becomes considerably more complicated. There is no generic version of SPRAVATO available, and the earliest estimates for a generic do not arrive until around 2028. that means for the foreseeable future, cost negotiations will involve insurance formularies, prior authorizations, and savings programs rather than cheaper alternatives on the pharmacy shelf.
What Happens During a SPRAVATO Treatment Session?
A typical session looks nothing like picking up a prescription. Patients arrive at a certified clinic or doctor’s office, self-administer the nasal spray under the supervision of a healthcare provider, and then remain at the facility for at least two hours of observation. During that monitoring period, staff check blood pressure, watch for dissociative symptoms, and assess overall stability before clearing the patient to leave. Patients cannot drive or operate heavy machinery for the rest of the day after treatment. During the induction phase, this happens twice a week.
For someone with a full-time job, that means arranging transportation and blocking out half-day windows twice weekly for a month. A caregiver who is the primary support for a family member with dementia would need to coordinate alternative care coverage for those sessions. These logistical demands are not trivial, and they are one of the reasons some eligible patients decline or discontinue treatment before completing the recommended course. The maintenance phase is less burdensome, dropping to once weekly or every two weeks. But even in maintenance, every single session requires the same in-office administration and two-hour monitoring period. This is not a medication that eventually transitions to home use.
SPRAVATO Side Effects and What to Expect After Each Dose
The side effect profile of SPRAVATO is unlike most antidepressants, and patients need to be prepared for that. Dissociation, described by patients as feeling detached from their body or surroundings, occurs in 41 to 61 percent of people. Sedation affects a similar proportion, ranging from 48 to 61 percent. Other common effects include dizziness, nausea, altered taste, headache, vertigo, and nasal discomfort. For many patients, these effects peak within the first hour and resolve by the end of the two-hour monitoring window. For others, the experience is unsettling enough to reconsider continued treatment.
The more serious risks deserve careful attention. Approximately 20 percent of patients experience blood pressure increases, which is particularly relevant for older adults or anyone already managing hypertension. Respiratory depression and loss of consciousness occur in a small fraction of patients, around 0.3 to 0.4 percent, but the consequences are serious enough to justify the mandatory in-office monitoring. There are also mental health risks: some patients may experience worsening depression or increased suicidal thoughts, especially early in treatment or during dose changes. One longer-term concern that does not get enough attention is the potential for bladder problems. Prolonged ketamine and esketamine use has been associated with ulcerative and interstitial cystitis. Patients on extended maintenance treatment should discuss bladder health monitoring with their provider, particularly if they notice urinary frequency, urgency, or pain.
How SPRAVATO Compares to IV Ketamine Clinics
One source of confusion is the difference between SPRAVATO and the IV ketamine infusions offered at private clinics across the country. Both are derived from ketamine, but they are not interchangeable. SPRAVATO is FDA-approved with specific indications, standardized dosing, and insurance billing codes. IV ketamine for depression is used off-label, meaning the FDA has not specifically approved that form of ketamine for that purpose. Off-label IV ketamine is rarely covered by insurance, and a single infusion typically costs $400 to $800 out of pocket. The tradeoff is nuanced.
IV ketamine clinics often offer more flexible scheduling and may not require the same two-hour monitoring window. Some patients report faster or more pronounced effects from IV administration. But the lack of FDA approval means less regulatory oversight, variable dosing protocols between clinics, and almost no insurance coverage. For patients who have insurance that covers SPRAVATO, the FDA-approved route is typically more affordable despite the higher list price. For uninsured patients or those whose plans exclude SPRAVATO, the math may tip toward IV ketamine, though both options carry similar risks. Neither option should be pursued without a thorough discussion with a psychiatrist who understands the patient’s full medical history, current medications, and cognitive status. This is especially true for older adults or those with early cognitive impairment, where the dissociative effects and blood pressure changes require extra caution.
Considerations for Older Adults and Dementia Caregivers
Depression is strikingly common among dementia caregivers, with research consistently showing rates two to three times higher than the general population. When that depression proves resistant to standard antidepressants, SPRAVATO enters the conversation. But older adults face additional layers of consideration. Blood pressure fluctuations are a greater concern.
The dissociative effects may be more disorienting. And the logistical demands of twice-weekly clinic visits during induction are harder to manage when you are also providing daily care for someone with cognitive decline. For caregivers specifically, the two-hour monitoring period plus the no-driving restriction effectively removes them from their caregiving role for an entire day, twice a week for a month. That is a significant commitment that requires a support network or respite care arrangement. It is worth having that conversation with family members or a care coordinator before starting treatment, rather than discovering midway through induction that the schedule is unsustainable.
What the 2025 Monotherapy Approval Means Going Forward
The January 2025 FDA decision allowing SPRAVATO as a standalone treatment for treatment-resistant depression is a meaningful development. Previously, patients were required to take an oral antidepressant alongside SPRAVATO, which meant managing additional side effects, drug interactions, and costs. For patients who had already failed multiple oral antidepressants, being required to continue one felt counterintuitive.
The monotherapy approval acknowledges that for some patients, SPRAVATO alone is sufficient. This also opens the door for broader research into esketamine’s role in other conditions. Studies are ongoing, and the expansion of approved indications over SPRAVATO’s relatively short history suggests further developments are possible. Whether future approvals might include populations with cognitive impairment or depression specifically linked to neurodegenerative disease remains to be seen, but the trajectory of the drug’s regulatory history suggests Janssen is actively pursuing expanded use cases.
Conclusion
SPRAVATO represents a genuine option for adults whose depression has not responded to at least two oral antidepressants, and the 2025 monotherapy approval removed one of the more frustrating barriers to its use. But it is not a simple or cheap solution. Treatment sessions cost $600 to $1,300 each, require in-office administration with two hours of monitoring, and come with a side effect profile that includes dissociation in roughly half of patients and blood pressure increases in about one in five.
Insurance and savings programs can bring costs down significantly, but access remains uneven, particularly for Medicare patients. For anyone considering SPRAVATO, the first step is a candid conversation with a psychiatrist about whether you meet the clinical criteria, what your insurance will cover, and whether the logistical demands of the treatment schedule are realistic given your daily life. If you are a caregiver for someone with dementia, factor in respite care needs during the induction phase. This is a treatment that demands planning, support, and ongoing monitoring, but for the right patient, it addresses a form of depression that has historically had very few effective options.
Frequently Asked Questions
Can SPRAVATO be prescribed by a primary care doctor?
SPRAVATO can only be administered in a certified healthcare setting enrolled in the REMS program. While a primary care physician could theoretically become certified, in practice most prescribers are psychiatrists, and the drug must be given in a clinic equipped for the required two-hour monitoring period.
Is SPRAVATO safe for people over 65?
SPRAVATO has been studied in older adults, but extra caution is warranted. Blood pressure increases, dizziness, and sedation may pose greater risks in this age group. A thorough cardiovascular evaluation and close monitoring are essential. Patients with uncontrolled hypertension should not use SPRAVATO.
How quickly does SPRAVATO work compared to traditional antidepressants?
Some patients report improvement within hours to days of their first dose, which is dramatically faster than the four to six weeks typical of oral antidepressants. However, responses vary widely, and the clinical trials measured sustained benefit over weeks, not individual session responses.
Can I take SPRAVATO at home?
No. Due to the REMS program requirements, every dose must be administered in a certified healthcare setting under supervision. There is no at-home option, and the nasal spray devices cannot be dispensed to patients for self-use outside of a clinic.
Does insurance typically cover SPRAVATO?
Many commercial insurance plans cover SPRAVATO, though prior authorization is almost always required. Medicare Part B may cover it in some cases, but coverage varies by plan. The Janssen withMe Savings Card can reduce copays to as low as $10 per session for eligible commercially insured patients, with up to $8,150 in annual savings.
Will a generic version of SPRAVATO be available soon?
Not in the near term. No generic esketamine nasal spray is currently available, and the earliest estimates for generic availability are around 2028.
